Last reviewed · How we verify
Glisepin (GLISOXEPIDE)
Glisepin (generic name: GLISOXEPIDE) is a glisoxepide drug. It is currently in Phase 2 development for Diabetes mellitus type 2.
Glisoxepide works by blocking potassium channels in the pancreas, allowing more insulin to be released.
Glisoxepide is a small molecule drug in the glisoxepide class that targets the sulfonylurea receptor 1, Kir6.2. It is used to treat diabetes mellitus type 2, but its commercial status and regulatory approval are unknown. As a sulfonylurea receptor 1 antagonist, glisoxepide works by inhibiting the closure of potassium channels in pancreatic beta cells, leading to increased insulin secretion. This mechanism helps to lower blood glucose levels in patients with type 2 diabetes. Further information on its pharmacokinetics and safety profile is not available.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GLISOXEPIDE |
|---|---|
| Drug class | glisoxepide |
| Target | Sulfonylurea receptor 1, Kir6.2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Mechanism of action
When you eat, your body breaks down the food into glucose, which is then released into your bloodstream. Normally, your pancreas releases insulin to help your cells absorb the glucose. Glisoxepide helps by keeping the potassium channels in your pancreas open, allowing more insulin to be released and helping your cells absorb the glucose more effectively.
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
- Incretin-based Drugs and Pancreatic Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glisepin CI brief — competitive landscape report
- Glisepin updates RSS · CI watch RSS
Frequently asked questions about Glisepin
What is Glisepin?
How does Glisepin work?
What is Glisepin used for?
What is the generic name of Glisepin?
What drug class is Glisepin in?
What development phase is Glisepin in?
What does Glisepin target?
Related
- Drug class: All glisoxepide drugs
- Target: All drugs targeting Sulfonylurea receptor 1, Kir6.2
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Diabetes mellitus type 2
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing